Nanomedicine News

RSS

Andain Develops Innovative Lipid-Based Nano-Particles Drug Delivery Technology

Andain Inc. ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its accelerating incubator program, announces today its innovative nano-particles drug delivery technology.

30 Apr 2013

Silica Nanorattle Coated Gold Nanoparticles Used for Dark Field Imaging

In recent years, metal nanoparticles have showed great application prospect in the field of biological imaging, cancer diagnosis and treatment due to its unique optical scattering and optical absorption properties.

30 Apr 2013

Nano Well Array Helps Achieve Single-Cell Resolution for Melanoma Study

A University of Houston engineering professor has won a grant from the Melanoma Research Alliance to help develop one of the most promising therapies for patients with the disease.

29 Apr 2013

UB Nanomaterial Researcher Wins Goldwater Scholarship

UB chemical engineering majors Christopher Dundas and Phillip Tucciarone are now part of the prestigious group of students receiving the Barry M. Goldwater Scholarship.

26 Apr 2013

T2 Magnetic Resonance Nanotechnology Solution Rapidly Detects Sepsis-Causing Fungus

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the publication of research supporting the Company's flagship diagnostic test, T2Candida®, in Science Translational Medicine.

25 Apr 2013

NanoViricides to Discuss its Broad Drug Pipeline at BIO International Convention

NanoViricides, Inc. (the "Company") announced today that its President, Dr. Anil Diwan, will present an overview of the company at the 2013 BIO International Convention being held at the McCormick Center in Chicago, Illinois from April 22 to 25, 2013 (http://convention.bio.org/).

From NanoViricides, Inc 25 Apr 2013

Intranasal Delivery of Novel Nanoparticles May Help Treat Parkinson's Disease

Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson's disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain.

24 Apr 2013

Covaris Debuts High Performance Formulation Processing System for Producing Nanosuspensions

Covaris, Inc. today announced the introduction of the FS220-M High Performance Formulation Processing System.

24 Apr 2013

ABL Reports Positive Results from Human-Ingestion Safety Study on Nano-Silver Particle Supplement

American Biotech Labs (ABL) has just released what is believed to be the first ever human-ingestion safety study on both a silver supplement, and also a nano-particle. The published abstract for the study states that ingestion of the patented ABL nano-silver particle showed no negative effects on any tested system in the body.

24 Apr 2013

BIND and AstraZeneca Partner to Commercialize Programmable Cancer Nanomedicine

BIND Therapeutics and AstraZeneca announced today that they have entered into a strategic collaboration to develop and commercialize an AccurinTM, a targeted and programmable cancer nanomedicine from BIND’s Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor developed and owned by AstraZeneca.

23 Apr 2013